Neurologic complications of immune checkpoint inhibitors
- 1 December 2016
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Neurology
- Vol. 29 (6), 806-812
- https://doi.org/10.1097/wco.0000000000000391
Abstract
In recent years, advances in the understanding of the regulatory mechanisms of the immune system has led to the development of new approaches for cancer treatment. Currently, immune checkpoint inhibitors are the first successful examples of this approach and several agents that target cytotoxic lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) have been approved for various oncologic situations. The aim of this review is to describe the neurologic adverse event profiles for these new immune therapeutic approaches and to discuss their appropriate management.The immune checkpoint inhibitor ipilimumab against CTLA-4 and nivolumab or pembrolizumab against PD-1 show a unique spectrum of toxic effects. The most common toxicities include rash, colitis, hepatitis, endocrinopathies, and pneumonitis. Neurologic side-effects are rare but include cases of immune polyneuropathies, Guillain Barré syndrome, myasthenia gravis, posterior reversible encephalopathy syndrome, aseptic meningitis, enteric neuropathy, transverse myelitis as well as immune encephalitis.It is essential that neurologic immune-related adverse events are recognized and treated as soon as possible, as early treatment increases the odds of a complete recovery.Keywords
This publication has 39 references indexed in Scilit:
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- Severe meningo-radiculo-nevritis associated with ipilimumabInvestigational New Drugs, 2012
- Overexpression of the CTLA-4 Isoform Lacking Exons 2 and 3 Causes AutoimmunityThe Journal of Immunology, 2012
- Exome sequencing identifies GRIN2A as frequently mutated in melanomaNature Genetics, 2011
- Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patientAnnals Of Oncology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Cellular and Synaptic Mechanisms of Anti-NMDA Receptor EncephalitisJournal of Neuroscience, 2010
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Vitiligo in patients with metastatic melanoma: A good prognostic signJournal of the American Academy of Dermatology, 1983